Johnson & Johnson reports Phase 4 STAR results showing TREMFYA reduced MRI-assessed sacroiliac joint inflammation and improved axial PsA disease activity.
Written By: Saniya Katakdhond, PharmD
Reviewed By: Pharmacally Editorial Team
Johnson & Johnson reported positive Week-24 results from its Phase 4 STAR study on November 20, 2026, showing that TREMFYA (guselkumab), a fully human monoclonal antibody that selectively blocks the interleukin-23 (IL-23) p19 subunit and has demonstrated CD64 binding in vitro, significantly improved axial disease activity and reduced MRI-assessed sacroiliac joint inflammation in biologic-naïve adults with active psoriatic arthritis (PsA) and axial involvement. The clinical significance of CD64 binding remains unknown. Presented as late-breaking data at the Emirates Society for Rheumatology (ESR) Annual Meeting, both evaluated dosing regimens met the primary and major secondary endpoints compared with placebo.
STAR Study Design and Patient Population
STAR (NCT04929210) is a multicentre, randomized, double-blind, placebo-controlled Phase 4 study evaluating guselkumab in biologic-naïve adults with active PsA and MRI-confirmed axial involvement. It is the first dedicated randomized, placebo-controlled study of an IL-23 inhibitor specifically designed to investigate this population using centrally read MRI assessments.
The study enrolled 411 participants. Eligible patients had MRI-confirmed axial inflammation and elevated C-reactive protein (CRP), despite previous treatment with non-biologic disease-modifying antirheumatic drugs (DMARDs), apremilast and/or nonsteroidal anti-inflammatory drugs (NSAIDs).
Participants received subcutaneous TREMFYA 100 mg or placebo at Weeks 0 and 4, followed by Q4W or Q8W dosing during the initial 24-week controlled period. The primary endpoint was the mean change from baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24.
Key Efficacy Results
Primary Endpoint: BASDAI Improvement
BASDAI is a six-component, patient-reported disease activity scale covering fatigue, spinal pain, peripheral joint pain, enthesial pain, and the severity and duration of morning stiffness. Each component is scored from 0 to 10, with the overall BASDAI score also ranging from 0 to 10. Higher scores indicate greater disease activity.
At Week 24, mean changes from baseline were:
- TREMFYA Q4W: −3.3 points
- TREMFYA Q8W: −2.9 points
- Placebo: −2.1 points
The negative values represent reductions in mean disease activity scores, indicating improvement in reported axial symptoms. Both TREMFYA regimens demonstrated statistically significant improvements compared with placebo.
Secondary Endpoint: ASDAS-CRP Improvement
The Ankylosing Spondylitis Disease Activity Score using CRP (ASDAS-CRP) is a composite measure combining back pain, morning stiffness, peripheral joint pain or swelling, patient global assessment and serum CRP concentration. Higher scores indicate greater disease activity.
At Week 24, mean changes from baseline were:
- TREMFYA Q4W: −1.5 score units
- TREMFYA Q8W: −1.3 score units
- Placebo: −0.8 score units
Both treatment groups exceeded the internationally recognized threshold of 1.1 score units for clinically important improvement. These findings indicate reductions in composite disease activity, incorporating both reported symptoms and an objective inflammatory biomarker.
MRI Findings: Reduction in Sacroiliac Joint Inflammation
Sacroiliac joint inflammation was assessed using the Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score. This validated imaging-based system evaluates bone marrow oedema across six consecutive MRI slices, incorporating its presence, intensity and depth. The total score ranges from 0 to 72, with higher scores indicating greater inflammatory activity.
At Week 24, mean changes from baseline were:
- TREMFYA Q4W: −7.1 points
- TREMFYA Q8W: −5.2 points
- Placebo: −2.4 points
These changes represented approximately threefold and 2.2-fold greater reductions with Q4W and Q8W, respectively, compared with placebo. The results provide objective imaging evidence of reduced sacroiliac joint inflammation alongside improvements in clinical disease activity.
Skin Response, Physical Function and Safety
TREMFYA demonstrated high levels of skin clearance with both dosing regimens, consistent with findings from DISCOVER I, DISCOVER II and APEX.
Improvement in the Health Assessment Questionnaire-Disability Index (HAQ-DI), which measures physical function and disability, was numerically greater with Q8W dosing but did not achieve statistical significance.
The overall safety profile observed in STAR was consistent with the established safety profile of TREMFYA in psoriatic disease, with no new safety signals identified. According to the US prescribing information, common adverse reactions in plaque psoriasis and PsA include upper respiratory infections, headache, injection-site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections and herpes simplex infections. These are established product-label adverse reactions and should not be interpreted as events specifically observed in STAR.
Clinical Significance and Study Implications
Axial involvement has been estimated to affect 25%–70% of patients with longer-standing PsA, contributing to inflammatory back pain, spinal stiffness and reduced mobility. However, axial PsA remains challenging to identify and evaluate because universally accepted diagnostic definitions and validated classification criteria specific to this manifestation are lacking.
STAR addresses an important evidence gap by combining patient-reported outcomes with centrally assessed MRI findings. Improvements in BASDAI and ASDAS-CRP indicate reduced clinical disease activity, while SPARCC results provide complementary imaging evidence of reduced inflammation.
However, the findings are limited to the 24-week placebo-controlled period and a biologic-naïve population. They do not establish long-term prevention of structural joint damage or superiority over other advanced therapies.
STAR includes an additional 24-week active-treatment period through Week 48, which will provide further information on response durability, MRI findings, physical function and safety. The Q4W regimen evaluated in STAR is not approved in the United States, and these findings do not establish a new approved dosing schedule.
Overall, STAR adds prospective, imaging-supported clinical evidence supporting further investigation of IL-23 inhibition in axial PsA, an understudied manifestation of psoriatic disease.
References
Johnson & Johnson. Johnson & Johnson Data in Psoriatic Arthritis (PsA) Shows TREMFYA (guselkumab) Is the Only Advanced Therapy to Demonstrate MRI-Confirmed Improvements in Spinal Pain and Stiffness. November 20, 2026
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease (STAR), ClinicalTrials.gov ID NCT04929210
About the Writer
Saniya Sanjay Katakdhond (Linkedin) is a Doctor of Pharmacy professional with hands-on experience in patient case review, clinical documentation, medical record analysis, and patient care.
Her hospital experience has strengthened her understanding of clinical conditions, treatment approaches, and multidisciplinary healthcare practices.
With ICH-GCP certification and a research-oriented approach, she brings clinical insight and attention to detail to healthcare content development.
As a healthcare writer, Saniya focuses on translating clinical knowledge and patient-care experience into clear, accurate, and evidence-informed medical content.
